Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the
canonical Wnt signaling bone formation pathway. Romosozumab is a humanized …

Increased understanding of bone biology has led to the discovery of several unique
signaling pathways that regulate bone formation and resorption. The Wnt signaling pathway …

Osteoporosis is a systemic bone disease characterized by low bone mass,
microarchitectural deterioration, increased bone fragility, and fracture susceptibility. It …

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture,
resulting in increased risk of fragility fractures and significant long-term disability. Although …

Increased understanding of the Wnt signaling pathway has led to the development of
romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis …

The glycoprotein sclerostin inhibits activation of the canonical Wnt pathway and thereby
suppresses bone formation by inhibiting the osteoblasts. Additionally, sclerostin increases …

Osteoporosis is a chronic skeletal disease with an increasing prevalence. Romosozumab,
as a monoclonal anti-sclerostin antibody with a dual function, has been produced. In this …

Abstract Purpose of Review Authors review the safety and efficacy of romosozumab for the
treatment of osteoporosis as demonstrated in three phase III clinical trials and offer insights …

Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for
postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency …

Romosozumab (Evenity®), a humanized monoclonal antibody, promotes bone formation
and inhibits bone resorption by inhibiting sclerostin, a protein involved in the regulation of …